TargetMol

CWI1-2 HCL

Product Code:
 
TAR-T67930L
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20°C
 

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T67930L-1mg1mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67930L-5mg5mg£416.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67930L-1mL1 mL * 10 mM (in DMSO)£515.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67930L-10mg10mg£581.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67930L-25mg25mg£863.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67930L-50mg50mg£1,163.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T67930L-100mg100mg£1,540.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CWI1-2 HCL is an effective IGF2BP2 inhibitor, which can induce apoptosis and differentiation by binding IGF2BP2 and inhibiting its interaction with M6A-modified target transcription, and has therapeutic effects on leukemia.
CAS:
2408590-37-2
Molecular Weight:
556.23
Pathway:
Apoptosis
Purity:
0.9918
SMILES:
OC1=CC=C(Cl)C=C1/C=N\N/C(N/N=C/C2=CC(Cl)=CC=C2O)=N/N=C/C3=CC(Cl)=CC=C3O.Cl
Target:
Apoptosis

References

Weng H, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022;40(12):1566-1582.e10.